Evelo Biosciences (NASDAQ:EVLO) Announces Quarterly Earnings Results

Evelo Biosciences (NASDAQ:EVLO) issued its earnings results on Tuesday. The company reported ($0.65) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.05), Bloomberg Earnings reports.

EVLO traded down $0.11 during trading hours on Wednesday, hitting $5.79. 91,199 shares of the company’s stock were exchanged, compared to its average volume of 41,850. Evelo Biosciences has a 1-year low of $4.90 and a 1-year high of $15.89. The firm has a 50-day moving average price of $7.86. The company has a market capitalization of $185.54 million, a PE ratio of -2.08 and a beta of -0.27. The company has a debt-to-equity ratio of 0.09, a quick ratio of 11.88 and a current ratio of 11.88.

Several research analysts have recently weighed in on EVLO shares. Jefferies Financial Group started coverage on shares of Evelo Biosciences in a report on Tuesday, April 30th. They issued a “buy” rating and a $18.00 price target for the company. ValuEngine upgraded shares of Evelo Biosciences from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Zacks Investment Research upgraded shares of Evelo Biosciences from a “hold” rating to a “buy” rating and set a $8.50 price target for the company in a report on Wednesday, July 17th. Cowen reiterated a “buy” rating on shares of Evelo Biosciences in a report on Thursday, May 2nd. Finally, Chardan Capital reiterated a “hold” rating and issued a $10.00 price target on shares of Evelo Biosciences in a report on Thursday, May 2nd. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Evelo Biosciences has a consensus rating of “Buy” and a consensus price target of $18.30.

Evelo Biosciences Company Profile

Evelo Biosciences, Inc, a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815, which are in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of atopic dermatitis, asthma, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases.

See Also: What is net income?

Earnings History for Evelo Biosciences (NASDAQ:EVLO)

Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.